Abstract:

OBJECTIVE: To understand the types and characteristics of anti-proliferative drug-eluting stent, and its effectiveness in clinical applications and problems to be solved.
METHODS: Using “intracoronary stent; cardiovascular disease; cell proliferation; drug-eluting; restenosis” as the Chinese key word, Chinese Academic Journal Full-text database was retrieved. Articles related to anti-proliferative drug-eluting stents to prevent restenosis were included. Meta analysis and reproduced study were excluded, a total of 16 literatures were selected.
RESULTS: Restenosis is the most obvious problem after percutaneous transluminal coronary angioplasty and stenting. Thrombosis, inflammation and smooth muscle hyperplasia are three major stages of in-stent restenosis, intimal hyperplasia is the most important mechanism of restenosis. The most commonly used anti-proliferative drugs are paclitaxel and rapamycin, and their derivatives. Rapamycin depresses restenosis occurrence and development by inhibiting intima and vascular smooth muscle cell proliferation, while paclitaxel by promoting endothelial cells and smooth muscle cell apoptosis.
CONCLUSION: Anti-proliferative drug-eluting stents have become the most potential approach to reduce the incidence of restenosis, but the restenosis is a complicated problem with several factors, drug-eluting stents study and application are still at the exploration stage, correct evaluation of drug-eluting stent will depend on a large sample of clinical scientific experiments.